Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, 0450, Oslo, Norway; Department of Endocrinology and Nutrition, August Pi i Sunyer Biomedical Research Institute - IDIBAPS, Hospital Clínic of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Faculty of Medicine, University of Oslo, 0372, Oslo, Norway.
Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, 0450, Oslo, Norway; Faculty of Medicine, University of Oslo, 0372, Oslo, Norway.
Clin Nutr. 2021 Dec;40(12):5674-5677. doi: 10.1016/j.clnu.2021.10.007. Epub 2021 Oct 20.
BACKGROUND & AIMS: Circulating microvesicles (cMV) are both effectors and biomarkers of cardiovascular disease (CVD), and the effects of omega 3 polyunsaturated fatty acids (n3 PUFA) in MV shedding are not yet well known. Therefore, we aimed to investigate the effects of long-term n3 PUFA supplementation on cMV release from cells of the vascular compartment in elderly subjects at very high risk of CVD.
We included 156 elderly patients 2-8 weeks after suffering an acute myocardial infarction from the OMEMI cohort. Subjects were randomly allocated to receive 930 mg EPA + 660 mg DHA (n3 PUFA intervention) or corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid) used as placebo daily for two years. At inclusion and after one-year follow-up, prothrombotic [annexin V (AV)] cMV derived from blood and vascular cells were phenotyped by flow cytometry.
No differences were observed in the levels of cMV between the randomized groups at inclusion in the study. After one-year follow-up, total AV, platelet-derived CD61/AV, and endothelial-derived CD31/AV and CD31/CD42b/AV cMV increased significantly in both groups. In the n3 PUFA supplemented group, platelet-derived CD62P/AV, CD42b/AV and CD31/CD42b/AV; leukocyte-derived CD62L/AV, CD45/AV, and CD11b/AV, as well as endothelial derived CD146/AV, CD62E/AV, and CD309/AV cMV also increased significantly. No significant differences were however, observed in the changes of cMV levels between groups.
In elderly Norwegians who have suffered a recent acute myocardial infarction and treated as per guidelines, long-term supplementation with 1.8 g/day n3 PUFA does not modulate prothrombotic MV release from blood and vascular cells.
URL: https://www.clinicaltrials.gov; Unique identifier: NCT01841944.
循环微泡（cMV）既是心血管疾病（CVD）的效应物也是生物标志物，而 ω-3 多不饱和脂肪酸（n3 PUFA）对 MV 脱落的影响尚不清楚。因此，我们旨在研究长期补充 n3 PUFA 对 CVD 高危老年患者血管细胞 cMV 释放的影响。
我们纳入了来自 OMEMI 队列的 156 名急性心肌梗死后 2-8 周的老年患者。患者被随机分配接受 930mg EPA+660mg DHA（n3 PUFA 干预组）或玉米油（56%亚油酸、32%油酸、10%棕榈酸）作为安慰剂，每日服用，持续 2 年。在纳入时和 1 年随访时，通过流式细胞术对来自血液和血管细胞的促血栓形成 [膜联蛋白 V（AV）] cMV 进行表型分析。
在研究纳入时，随机分组之间 cMV 水平无差异。1 年随访后，两组总 AV、血小板衍生的 CD61/AV 和内皮衍生的 CD31/AV 和 CD31/CD42b/AV cMV 均显著增加。在 n3 PUFA 补充组中，血小板衍生的 CD62P/AV、CD42b/AV 和 CD31/CD42b/AV；白细胞衍生的 CD62L/AV、CD45/AV 和 CD11b/AV，以及内皮衍生的 CD146/AV、CD62E/AV 和 CD309/AV cMV 也显著增加。然而，两组间 cMV 水平的变化无显著差异。
在近期急性心肌梗死后按指南治疗的挪威老年人中，长期补充 1.8g/d n3 PUFA 不会调节血液和血管细胞中促血栓形成的 MV 释放。
